This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date01 Dec 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07179120

/ Not yet recruitingPhase 2IIT

Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial

Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving.
What will happen in this study?
This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups:
Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts.
Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated.
Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated.
All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up.
Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join.
How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates.
What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

Start Date01 May 2026

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

NCT06820281

/ Not yet recruitingPhase 2IIT

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)

This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 4 weeks of treatment with TZP. These measures will also be compared to a group of adults without diabetes (who will not receive treatment with TZP) to assess how metabolism of energy and nutrients is different in T1D compared to people without diabetes.

Start Date01 Dec 2025

Sponsor / Collaborator

The Garvan Institute of Medical Research

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

1,363

Literatures (Medical) associated with Tirzepatide

01 Feb 2026·TISSUE & CELL

Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model

Article

Author: Marinho, Thatiany S ; Aguila, Marcia B ; Marcondes-de-Castro, Ilitch A ; Mandarim-de-Lacerda, Carlos A

The effects on hepatic mitochondrial structure, mitophagy, and cellular homeostasis were investigated when treated with Tirzepatide (Tzp), a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and menopause-conditions that collectively exacerbate metabolic dysfunction-associated steatotic liver disease (MASLD). Female C57BL/6 mice were fed either a control or high-fat, high-sucrose diet for 12 weeks, and half underwent bilateral ovariectomy to simulate menopause. Tzp was administered daily for four weeks. Liver tissue was evaluated for ultrastructural alterations, gene expression, and protein profiles. Untreated obese-diabetic and obese-diabetic-ovariectomized mice exhibited hepatocellular fat accumulation, mitochondrial swelling, and disorganized cristae, indicative of metabolic and oxidative stress. In contrast, Tzp-treated mice displayed preserved hepatic architecture and intact mitochondrial morphology. Tzp significantly downregulated autophagy genes (Ulk3, Atg5, Atg7) and key mitophagy regulators (PINK1, PRKN), reestablishing mitochondrial balance, primarily through the modulation of mitophagy and enhanced organelle stability. Simultaneously, it upregulated mitochondrial biogenesis markers (Ppargc1a, Tfam), antioxidant enzymes (SOD2, GR, GPX, CAT), and redox modulators (Sirt3, Nrf2), while normalizing oxidative stress-related genes (Nos1, Nox1). Tzp also mitigated endoplasmic reticulum (ER) stress by downregulating Atf4, Ddit3, and Gadd45 and rebalanced mitochondrial dynamics through the suppression of fission markers (Dnml1, Fis1) and the restoration of fusion mediators (Mfn1, Mfn2). Three-way ANOVA confirmed Tzp's broad regulatory effects on hepatic gene expression, while principal component analysis revealed clear transcriptional separation between treated and untreated groups. In conclusion, these findings demonstrate that Tzp preserves liver ultrastructure and restores mitochondrial dynamics, supporting its therapeutic potential in MASLD and hormone-related metabolic disorders.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

Author: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

01 Dec 2025·Current Cardiovascular Risk Reports

Triple Agonism Based Therapies for Obesity

Review

Author: Papamargaritis, Dimitris ; Surti, Farhaana ; Goldney, Jonathan ; Hamza, Malak ; Davies, Melanie J

Abstract:

Purpose of the Review:

Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management. Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies. Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors represent a promising next step. This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate.

Recent Findings:

Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D. Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks. In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%. Retatrutide also improved multiple cardiometabolic parameters, including blood pressure, lipids, waist circumference, and liver fat (82% reduction in hepatic steatosis). Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed. A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D. Other unimolecular triple agonists and combination regimens involving tirzepatide with additional mono agonists are also in development.

Summary:

Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.

1,448

News (Medical) associated with Tirzepatide

22 Sep 2025

·www.fiercepharma.com

In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy

With a deadline looming for President Donald Trump's most favored nation drug pricing effort, Bristol Myers Squibb says it will charge the same in the U.K. as it does in the U.S. for new schizophrenia drug Cobenfy. With a Sept. 29 deadline looming for pharmaceutical companies to adhere to President Donald Trump’s most favored nation (MFN) drug pricing system in the U.S., Bristol Myers Squibb has taken the unusual step of revealing the price it plans to charge in the U.K. for its new schizophrenia treatment Cobenfy.The New Jersey company will offer the drug "at a UK list price equal to the US list price," according to a press statement Monday. In the U.S., the drug carries a monthly list price of $1,850, according to a BMS website, which equates to $22,200 annually.BMS is submitting for approval later this year, with plans to launch Cobenfy in the U.K. in 2026, according to the statement.While analysts have characterized Trump’s MFN executive order as having more bark than bite and likely being subject to future legal challenges, the initiative is designed to match the costs of prescription drugs in the U.S. to the lowest price offered in other developed nations.In late July, Trump sent letters to 17 of the world’s largest drugmakers outlining steps they “must take” to moderate the costs of their U.S. medicines in line with international reference prices.“By making this commitment with Cobenfy, we are asking the UK to step up in recognizing the value of truly innovative therapies,” BMS Chief Commercial Officer Adam Lenkowsky said in a statement. “We agree with the Trump administration that other countries need to pay their fair share," he added.It is the first time that BMS has priced a drug in the U.K. the same as it charges in the U.S. As an example, while BMS charges $7,943 for a 240-mg dose of blockbuster cancer drug Opdivo in the U.S., the same dose is priced at 2,633 pounds sterling ($3,556) in England. In the U.K.—where pharmaceuticals are provided through the publicly funded National Health Service—prices are subject to cost/benefit scrutiny before medicines are made widely available. England's National Institute for Health and Care Excellence is notorious in the pharma industry for drawing a hard line in pricing assessments, so BMS' announcement is sure to set up a heated review process for the novel schizophrenia treatment.Crucially, while list prices are publicly known, pharma companies and U.K. officials regularly negotiate confidential discounts that enable patient access at acceptable costs to the government.BMS intends to work with U.K. regulators to make Cobenfy available, Lenkowsky said.“But we are prepared to make the difficult decision to walk away if they cannot better recognize the value our medicine brings to patients and society,” he added.The U.K. would become the first nation in Europe where Cobenfy would be approved. It is a key advancement in the treatment of schizophrenia as it offers a new mechanism of action to the dopamine receptors which currently dominate the market in the indication. The move by BMS comes as the U.K. government faces pressure from biopharma companies to reduce its heavy taxes on drugs and to provide more incentives for investment. Earlier this month, AstraZeneca paused a 200 million pound sterling ($271 million) investment in a research site the company planned near its headquarters in Cambridge.Besides AZ, several other pharma giants made headlines this month for their recent decisions to pull back from the country or pause future U.K. R&D investments.During his first term, Trump made a similar effort to reduce drug prices through a MFN structure, but it failed to survive court challenges.While the executive order was designed to force companies to reduce their prices in the U.S., it also can compel them to raise prices in other developed countries. In August, for example, shortly after receiving an MFN letter from Trump, Eli Lilly said it planned to jack up the price of blockbuster diabetes treatment Mounjaro by as much as 170% in the U.K.Then, three weeks ago, Lilly temporarily stopped taking U.K. orders for Mounjaro, citing legal protections from stockpiling by providers in anticipation of the price adjustment.

Accelerated Approval

22 Sep 2025

·endpoints.news

Post-Hoc: Threatening the UK to send a message to the rest of Europe

Over the last month or two, big international drugmakers have been beating up on a little country to send a message to its neighbors. In August, Eli Lilly announced it would raise prices in the UK for Mounjaro, its anti-obesity drug. This month, Merck, AstraZeneca and Lilly put plans on hold to expand their UK R&D investment. And on Monday, Bristol Myers Squibb said it would price its schizophrenia drug Cobenfy at US prices for the UK , saying “a new approach is needed” in the UK — and threatening not to bring the drug there if the government doesn’t play ball. Over and over this year, major pharma companies have criticized the business environment in the UK, pulled back on prior commitments, and said they would raise prices — daring the UK not to cover the products. It’s hard not to look at what’s happening and see the industry making a high-profile example of a small country. Even GSK — one of the UK’s crown jewels — has made the stakes clear. When I met with her in New York earlier this month, CEO Emma Walmsley said things have to improve. “The UK is 2% of our sales, and the US is 52% of our sales and our number one priority for investment,” Walmsley said. “The UK has said that life sciences is a strategic industry, and it has the footprint and the businesses to do that, but that is only possible if the commercial environment improves.” (Plenty of other companies and executives have made similar comments.) Drugmakers’ messages, though, are aimed just as much at the US as they are at Europe. Pharma is in the middle of “most favored nation” talks with the Trump administration. And a big part of President Donald Trump’s policy is getting US and European prices closer in line. The world’s large drugmakers have no intention of losing money by charging less in the US, which means they’ll pressure the rest of the world to pay more. But to make that happen, they need to wield a legitimate threat. The UK makes sense as a target for that effort. It’s an English-speaking media market that Trump has singled out as getting advantageous prices. By raising prices and pulling projects, pharma’s message to the rest of Europe is clear: Go along, or we’ll do to you what we’re doing to the UK. (While the UK has faced the bulk of the actions, companies have made a handful of similar warnings elsewhere around Europe.) Pharma’s threats to Europe almost certainly play well in the US, too. In Washington, the negotiations over “most favored nation” pricing are far from resolving the administration’s ambitious goals, despite just a week until Trump’s self-imposed Sept. 29 deadline. I’ve spoken to several large drugmakers who have said that the talks have been a mess and are far from hitting the policies laid out by Trump. But by beating up on the UK and Europe, the industry may end up buying itself some leeway, or at least some time. Even if the US government and pharma can’t solve US drug pricing, they can at least make Europe feel some pain. And in Trump’s “if you lose, I win” view of international drug prices, that may be seen favorably by the White House. — Drew

22 Sep 2025

·endpoints.news

Bristol Myers to launch schizophrenia drug in the UK at the same price as in the US

In a company first, Bristol Myers Squibb said it plans to launch its schizophrenia drug in the UK with the same list price as in the US, as tension between drugmakers and the UK government continues to build. Cobenfy, which the FDA approved last year, has a list price of $22,500 a year in the US. The move would mark the first time a pharma company has set a drug’s UK price at its US level, following President Donald Trump’s ongoing push to bring US drug prices in line with what companies charge abroad. BMS plans to file a marketing authorization application for the drug (xanomeline and trospium chloride) with UK regulators later this year. “It’s rare for a company to disclose its UK pricing plans weeks before it intends to submit a marketing authorization application. It’s also very unusual to seek pricing parity with the US market,” independent global market access consultant Neil Grubert told Endpoints News. The announcement comes during a time of increasing industry concern in the UK over what it says is a lack of government action to improve the life science investment space. The company is still willing “to walk away” from the UK if the country’s National Health Service and National Institute for Health and Care Excellence fail to see the value of its medicine, BMS chief commercialization officer Adam Lenkowsky told Endpoints on Monday. He said BMS agrees with the Trump administration that other countries need to “pay their fair share” for drugs. The company said last week that the UK pays too little for medicines . The UK government is under pressure from biopharma companies as they call out the high payback taxes for medicines in the country, which is the portion of sales a drugmaker pays back to the NHS. The UK’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth stands at nearly 23%, which is much higher compared to other countries. Drugmakers like Eli Lilly, AstraZeneca and Merck have reconsidered new builds in the UK after the government failed to strike a deal with drugmakers on medicine pricing in early September. Some smaller biotechs are now saying they are avoiding new drug launches in the UK due to the high taxes. At the same time, the White House is zeroing in on reducing drug prices in the US, spurring some drugmakers to raise their prices elsewhere. President Trump sent 17 letters to companies , including Bristol Myers, demanding that they lower prices to match those in other “most favored” nations. Last month, Lilly announced plans to raise the list price of its weight loss drug Mounjaro in the UK, to £330 ($446) from £122 ($165) for a month’s supply of the highest dose, noting it had to raise prices in other countries in order to lower them in the US. Editor’s note: This story has been updated with a quote from independent global market access consultant Neil Grubert.

Drug ApprovalAccelerated Approval

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Czechia	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Denmark	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	France	Eli Lilly & Co.	26 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05822830 (SURMOUNT-5, NEWS) Manual	Phase 3	Obesity	-	Tirzepatide	vsnnwynlon(dlboxkgidu) = btptptpjjj nzvrjmgbls (kcayljzisr ) View more	Positive	01 Sep 2025
				Semaglutide	vsnnwynlon(dlboxkgidu) = vnigqtuizr nzvrjmgbls (kcayljzisr ) View more
NCT04311411 (Pubmed \| Nat Med)	Phase 1	Overweight \| Obesity	114	Tirzepatide	anytjixjea(sltmgrtvzi) = vnyweuomla leqrxkfmik (oiiulceedj, -648.1 to -401.0)	Positive	01 Sep 2025
				Placebo	-
NCT06914141 \| NCT06914154 \| NCT06914102 (JAMA) Manual	Not Applicable	Heart failure with normal ejection fraction	97,790	Semaglutide	ajihogtrmt(wuktwjhxbe): HR = 0.58 (95.0% CI, 0.51 - 0.65) View more	Positive	31 Aug 2025
				sitagliptin
NCT05696847 (CTgov)	Phase 1	Obesity	28	Placebo (Cohort 1: Placebo (BW >=50 kg))	shjqxxwmep = xqmruugpvd pbzgrkwqsm (lxrnomqufm, cknplrdiyg - dozwxrflqv) View more	-	26 Aug 2025
				Tirzepatide (Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg))	shjqxxwmep = umoexrvpij pbzgrkwqsm (lxrnomqufm, envodxtzor - avvivyaqju) View more
NCT04847557 (SUMMIT, CTgov)	Phase 3	Heart failure with normal ejection fraction \| Obesity	731	Placebo	zkfojagzzd(xljzrorftt) = bobyvkcgxt idtcksugst (ohmnblmkzn, 1.25) View more	-	20 Aug 2025
NCT05691712 (SURPASS-CN-INS, CTgov)	Phase 3	Diabetes Mellitus, Type 2	257	Tirzepatide (10 mg Tirzepatide)	zwhgdlqfdl(urdqpbzvao) = swrclshpew xazyxyiccr (jggycoxfkp, 1.367) View more	-	08 Aug 2025
				Tirzepatide (15 mg Tirzepatide)	zwhgdlqfdl(urdqpbzvao) = cudqgrmcio xazyxyiccr (jggycoxfkp, 1.386) View more
NCT05564039 (SURPASS-SWITCH, CTgov)	Phase 4	Diabetes Mellitus, Type 2	282	Dulaglutide	bciarjofkf(mngfumttay) = xbcnnffgvj uuqsisrruc (bnsbapdktl, 0.074) View more	-	03 Aug 2025
NCT04184622 (SURMOUNT-1, Pubmed \| Ann Intern Med)	Phase 3	Obesity	1,605	Tirzepatide 5 mg	ojsytaucrt(sjgucoggig) = slbniabedo favwuusrwa (ylbcviaokd, -63.6% - -55.3%) View more	Positive	01 Aug 2025
NCT04255433 (SURPASS-CVOT, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,299	Mounjaro (tirzepatide)	jirqxyiqhs(naahjbebns): HR = 0.92 (95.3% CI, 0.83 - 1.01) Met View more	Non-inferior	31 Jul 2025
				Trulicity (dulaglutide)
NCT04255433 (SURPASS-CVOT, ADA 12025 \| ADA 22025) Manual	Phase 3	Diabetes Mellitus, Type 2	15,775	Tirzepatide (overall cohort)	meuhisplhg(ksgqzwbaxk) = vdktzjizdl wgojkonypn (yegzezqxzl )	Positive	20 Jun 2025
				Dulaglutide (overall cohort)	meuhisplhg(ksgqzwbaxk) = lyhjnwbili wgojkonypn (yegzezqxzl )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis